Acor­da writes off $363M drug, ax­ing PhI­II Parkin­son’s drug in the wake of 5 pa­tient deaths

Five days af­ter Acor­da said it was sus­pend­ing en­roll­ment af­ter track­ing the deaths of 5 pa­tients from sep­sis in a late-stage study of the Parkin­son’s drug tozadenant, the deeply trou­bled biotech says it’s de­cid­ed to scrap the drug al­to­geth­er as too dan­ger­ous to keep in the clin­ic.

Ac­cord­ing to Acor­da, re­searchers tracked new in­for­ma­tion about its num­ber two drug in the pipeline that con­vinced the com­pa­ny to dis­con­tin­ue the work on a drug that cost them $363 mil­lion in an all-cash buy­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.